Menu
Search
|

Menu

Close
X

Sinovac Biotech Ltd SVA.OQ (NASDAQ Stock Exchange Global Select Market)

8.19 USD
+0.07 (+0.86%)
As of 2:29 AM IST
chart
Previous Close 8.12
Open 8.12
Volume 3,110
3m Avg Volume 54,226
Today’s High 8.20
Today’s Low 8.12
52 Week High 8.58
52 Week Low 4.60
Shares Outstanding (mil) 56.91
Market Capitalization (mil) 399.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY16
72
FY15
67
EPS (USD)
FY16
-0.052
FY15
-0.012
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
6.25
5.77
Price to Book (MRQ)
vs sector
3.47
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
32.87
16.52
LT Debt to Equity (MRQ)
vs sector
5.18
12.22
Return on Investment (TTM)
vs sector
-6.06
14.43
Return on Equity (TTM)
vs sector
-5.15
16.13

EXECUTIVE LEADERSHIP

Weidong Yin
Chairman of the Board, President, Chief Executive Officer, Secretary, Since 2003
Salary: $46,079.00
Bonus: $59,553.00
Nan Wang
Chief Financial Officer, Since 2013
Salary: --
Bonus: --
Ming Xia
Vice President - Sales and Marketing of Sinovac Beijing, Since 2011
Salary: --
Bonus: --
Simon Anderson
Independent Director, Since 2004
Salary: --
Bonus: --
Jue Lee
Independent Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

39 Shangdi Xi Road, Haidian Dist
BEIJING   BEJ   100085

Phone: +8610.82890088

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

SPONSORED STORIES